Treatments for Viral Hepatitis and Liver Fibrosis
The development of a drug to treat hepatitis C virus (HCV) is progressing rapidly. With the advent of interferon alfa monotherapy combined with triple therapy with peginterferon alfa and ribavirin, the chance of recovery in patients with HCV genotype 1 has increased from <10% to 70%.
Liver fibrosis can be caused by a number of factors, eventually leading to cirrhosis. In fact, liver fibrosis and cirrhosis represent all health problems. Advances in liver transplantation, the treatment of portal hypertension, and the treatment of chronic obstructive pulmonary disease have produced significant results.
However, these approaches are not without obstacles, especially the issues related to the accessibility of the organ for transplantation, and show the urgent need to provide a therapeutic effect to the fibrotic process under number of patients.
Hepatitis Conference | Hepatitis Congress | Hepatitis Meeting | Hepatitis Summit | Hepatitis Expo | Hepatitis Meet | Liver Conference | Liver Congress | Liver Summit | Liver Meeting | Liver Expo | Liver Meet
